1. Home
  2. EWTX vs NTST Comparison

EWTX vs NTST Comparison

Compare EWTX & NTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • NTST
  • Stock Information
  • Founded
  • EWTX 2017
  • NTST 2019
  • Country
  • EWTX United States
  • NTST United States
  • Employees
  • EWTX N/A
  • NTST N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • NTST Real Estate Investment Trusts
  • Sector
  • EWTX Health Care
  • NTST Real Estate
  • Exchange
  • EWTX Nasdaq
  • NTST Nasdaq
  • Market Cap
  • EWTX 1.5B
  • NTST 1.3B
  • IPO Year
  • EWTX 2021
  • NTST 2020
  • Fundamental
  • Price
  • EWTX $13.03
  • NTST $17.07
  • Analyst Decision
  • EWTX Buy
  • NTST Strong Buy
  • Analyst Count
  • EWTX 9
  • NTST 8
  • Target Price
  • EWTX $39.89
  • NTST $18.16
  • AVG Volume (30 Days)
  • EWTX 892.5K
  • NTST 939.7K
  • Earning Date
  • EWTX 08-07-2025
  • NTST 07-23-2025
  • Dividend Yield
  • EWTX N/A
  • NTST 5.00%
  • EPS Growth
  • EWTX N/A
  • NTST N/A
  • EPS
  • EWTX N/A
  • NTST N/A
  • Revenue
  • EWTX N/A
  • NTST $171,021,000.00
  • Revenue This Year
  • EWTX N/A
  • NTST $12.84
  • Revenue Next Year
  • EWTX N/A
  • NTST $6.47
  • P/E Ratio
  • EWTX N/A
  • NTST N/A
  • Revenue Growth
  • EWTX N/A
  • NTST 22.05
  • 52 Week Low
  • EWTX $10.60
  • NTST $13.42
  • 52 Week High
  • EWTX $38.12
  • NTST $17.53
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 35.20
  • NTST 63.36
  • Support Level
  • EWTX $12.72
  • NTST $16.45
  • Resistance Level
  • EWTX $13.37
  • NTST $17.20
  • Average True Range (ATR)
  • EWTX 0.65
  • NTST 0.35
  • MACD
  • EWTX -0.16
  • NTST 0.02
  • Stochastic Oscillator
  • EWTX 24.22
  • NTST 88.15

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About NTST NetSTREIT Corp.

Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.

Share on Social Networks: